Comparative Pharmacology
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus LOPERAMIDE HYDROCHLORIDE.
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus LOPERAMIDE HYDROCHLORIDE.
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE vs LOPERAMIDE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate acts as an opioid agonist on mu-opioid receptors in the gastrointestinal tract, reducing peristalsis and increasing intestinal transit time. Atropine sulfate is added at subtherapeutic doses to deter abuse by causing unpleasant anticholinergic effects at high doses.
Loperamide binds to µ-opioid receptors in the intestinal wall, reducing propulsive peristalsis and increasing intestinal transit time. It also inhibits calcium-calmodulin-dependent pathways, decreasing electrolyte and water secretion, and enhances anal sphincter tone.
2.5-5 mg (diphenoxylate) orally 4 times daily until diarrhea controlled; maximum 20 mg/day (diphenoxylate).
4 mg orally initially, followed by 2 mg after each unformed stool; maximum 16 mg per day. For chronic diarrhea, 4 mg orally once, then 2 mg after each unformed stool until diarrhea controlled; typical maintenance 4-8 mg daily in divided doses. Traveler's diarrhea: 4 mg initially, then 2 mg after each loose stool; maximum 8 mg per day for up to 2 days.
None Documented
None Documented
Diphenoxylate: terminal half-life of 2.9-5.8 hours (active metabolite difenoxin: 12-14 hours). Atropine: terminal half-life of 2-4 hours. Clinical context: The long half-life of difenoxin contributes to sustained antidiarrheal effect.
Terminal elimination half-life is 9-14 hours (mean 10.8 hours) in adults; may be prolonged in hepatic impairment.
Diphenoxylate is excreted primarily in feces (via biliary elimination) as the active metabolite difenoxin and its conjugates; approximately 14% is excreted renally as unchanged drug and metabolites. Atropine is excreted renally (30-50% unchanged) and partially in feces.
Primarily fecal (30-40% as unchanged drug, 50-60% as metabolites); renal excretion accounts for <5% of unchanged drug and ~10% of metabolites.
Category C
Category A/B
Antidiarrheal
Antidiarrheal